Log on / register
Feedback | Support | My details

Comments

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Sandro Pignata email, Giovanni Scambia email, Antonella Savarese email, Enrico Breda email, Paolo Scollo email, Rocco De Vivo email, Emanuela Rossi email, Vittorio Gebbia email, Donato Natale email, Filomena Del Gaizo email, Emanuele Naglieri email, Antonella Ferro email, Pietro Musso email, Alfonso Maria D'Arco email, Roberto Sorio email, Carmela Pisano email, Massimo Di Maio email, Giuseppe Signoriello email, Annalisa Annunziata email and Francesco Perrone email for the MITO Investigators (see appendix)

BMC Cancer 2006, 6:202doi:10.1186/1471-2407-6-202

No comments have yet been made on this article

Post a comment

Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.